Next Article in Journal
Ubiquitin in Influenza Virus Entry and Innate Immunity
Next Article in Special Issue
Studies in a Murine Model Confirm the Safety of Griffithsin and Advocate Its Further Development as a Microbicide Targeting HIV-1 and Other Enveloped Viruses
Previous Article in Journal
The Microtubule Inhibitor Podofilox Inhibits an Early Entry Step of Human Cytomegalovirus
Previous Article in Special Issue
A Designed “Nested” Dimer of Cyanovirin-N Increases Antiviral Activity
Article Menu

Export Article

Open AccessReview
Viruses 2016, 8(10), 296; doi:10.3390/v8100296

Griffithsin: An Antiviral Lectin with Outstanding Therapeutic Potential

Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Barry R. O’Keefe
Received: 2 September 2016 / Revised: 10 October 2016 / Accepted: 13 October 2016 / Published: 24 October 2016
(This article belongs to the Special Issue Lectins as Antiviral)
View Full-Text   |   Download PDF [8109 KB, uploaded 24 October 2016]   |  

Abstract

Griffithsin (GRFT), an algae-derived lectin, is one of the most potent viral entry inhibitors discovered to date. It is currently being developed as a microbicide with broad-spectrum activity against several enveloped viruses. GRFT can inhibit human immunodeficiency virus (HIV) infection at picomolar concentrations, surpassing the ability of most anti-HIV agents. The potential to inhibit other viruses as well as parasites has also been demonstrated. Griffithsin’s antiviral activity stems from its ability to bind terminal mannoses present in high-mannose oligosaccharides and crosslink these glycans on the surface of the viral envelope glycoproteins. Here, we review structural and biochemical studies that established mode of action and facilitated construction of GRFT analogs, mechanisms that may lead to resistance, and in vitro and pre-clinical results that support the therapeutic potential of this lectin. View Full-Text
Keywords: carbohydrate binding agent; viral envelope glycoproteins; multivalency; resistance; immunogenicity; HIV; HSV; HCV carbohydrate binding agent; viral envelope glycoproteins; multivalency; resistance; immunogenicity; HIV; HSV; HCV
Figures

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Lusvarghi, S.; Bewley, C.A. Griffithsin: An Antiviral Lectin with Outstanding Therapeutic Potential. Viruses 2016, 8, 296.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top